



by
Boehringer Ingelheim

SMARCA2/4 PROTAC

ACBI1

Table of contents

Summary	2
Chemical Structure.....	2
Highlights.....	3
Target information.....	3
<i>In vitro</i> activity.....	4
<i>In vitro</i> DMPK and CMC parameters	5
<i>In vivo</i> DMPK parameters.....	5
Negative control.....	6
Selectivity.....	7
Co-crystal structure of the Boehringer Ingelheim probe compound and the target protein.....	9
Reference molecule(s).....	9
Supplementary data	9
References.....	9

Highlights

ACBI1 is a potent and cooperative PROTAC degrader of the BAF complex subunits SMARCA2, SMARCA4 and PRBM1. It harnesses the VHL E3 ligase to recruit its targets via their bromodomains, which results in their selective and pronounced degradation. This compound is suitable for both *in vitro* and *in vivo* studies and may be a useful tool to study the effects of an acute inactivation of the BAF complex.

Target information

The ATP-dependent activities of the BAF (SWI/SNF) chromatin remodeling complexes affect the positioning of nucleosomes on DNA and thereby many cellular processes related to chromatin structure, including transcription and DNA repair. The SMARCA2 and SMARCA4 genes code for the two alternative catalytic ATP-dependent helicases of the complex. Subunits of the BAF complexes are mutated in approximately 20% of human cancers. Several types of cells have been shown to be vulnerable to the loss of BAF complex ATPase subunits and subunits of the BAF complexes have been found to be mutated in approximately 20% of human cancers. Acute myeloid leukemia cells are sensitive to the loss of SMARCA4, whereas SMARCA4 mutant cancer cells are sensitive to the loss of SMARCA2. Future studies are warranted towards deeper mechanistic understanding of the downstream effects of degrading BAF ATPase subunits in both cancerous and non-cancerous cells. We hope that progress in this direction will be greatly advanced by sharing the chemical tool that has emerged from our work with the wider community.

ACBI1 is a PROTAC* that causes degradation of SMARCA2 and SMARCA4, as well as the facultative BAF complex subunit PBRM1. It is useful to study the consequences of inactivation of the BAF complex in cells *in vitro*, such as effects on chromatin accessibility, transcription and proliferation¹⁻⁵ and can be also used for *in vivo* studies.

The compound is the result of a collaboration between the University of Dundee, School of Life Sciences, and Boehringer Ingelheim.

*PROTACs (proteolysis-targeting chimeras) offer a novel drug modality wherein bi-functional molecules recruit a target protein and an E3 ligase to induce ubiquitylation and subsequently proteasomal degradation of the target protein.




Figure 3: ACBI1 analog in ternary co-crystal structure of SMARCA2BD:ACBI1analog:VCB (PDB ID 6HAX)

***In vitro* activity**

ACBI1 causes degradation of its targets in tissue culture cells.

PROBE NAME / NEGATIVE CONTROL	ACBI1	cis-ACBI1
MW [Da, free base] ^a	936.1	936.1
Degradation of SMARCA2 in MV-4-11 cells (IC ₅₀) [nM] ^b	6	>1,000
Degradation of SMARCA4 in MV-4-11 cells (IC ₅₀) [nM] ^b	11	>1,000
Degradation of PBRM1 in MV-4-11 cells (IC ₅₀) [nM] ^b	32	>1,000
Proliferation assay in MV-4-11 cells (IC ₅₀) [nM] ^c	29	1,400
Proliferation assay in SK-MEL-5 cells (IC ₅₀) [nM] ^c	77	>10,000

^a For the salt form you will get, please refer to the label on the vial and for the molecular weight of the salt, please refer to the FAQs

^b Treatment for 18 h followed by analysis by capillary electrophoresis

^c Treatment for 7 days before measuring cell viability via cellular ATP content

In vitro DMPK and CMC parameters

PROBE NAME / NEGATIVE CONTROL	ACBI1	cis-ACBI1
logD @ pH 11	4.3	4.5
Solubility @ pH 7 [$\mu\text{g}/\text{mL}$]	<1	<1
Caco-2 permeability AB @pH7.4 [$*10^{-6}$ cm/s]	2.2	n.d.
Caco-2 efflux ratio	1.7	n.d.
Microsomal stability (human/mouse/rat) [% Q_H]	86 / 46 / <23	>88 / 53 / 34
Hepatocyte stability (human/mouse/rat) + 50% plasma [% Q_H]	- / 62 / 41	n.d.
Plasma Protein Binding (FCS 10%) [%]	>99.4	>89.2
CYP 3A4 (IC_{50}) [μM]	0.4	n.d.
CYP 2C8 (IC_{50}) [μM]	<0.2	n.d.
CYP 2C9 (IC_{50}) [μM]	>50	n.d.
CYP 2C19 (IC_{50}) [μM]	1.3	n.d.
CYP 2D6 (IC_{50}) [μM]	>50	n.d.

In vivo DMPK parameters

ACBI1	MOUSE ^A	RAT ^B
Clearance [% Q_H]	7.3	93
Mean residence time after <i>i.v.</i> dose [h]	0.8	2.8
t_{max} [h]	0.33	1.5

V_{ss} [L/kg]	0.32	12
F [%]	100	100

^a i.v. dose: 5 mg/kg; s.c. dose: 5 mg/kg

^b i.v. dose: 5 mg/kg; s.c. dose: 5 mg/kg




Figure 4: PK profiles of ACBI1 upon 5 mg/kg i.v. (blue curves) and 5 mg/kg s.c. dosing (green curves) in mouse and rat.

Negative control

In the negative control compound, *cis*-ACBI1, the hydroxy proline of the VHL binding part is in the inactive *cis*-conformation, which prevents binding to VHL and thereby protein degradation. This prevents binding to VHL, formation of a triple complex and thereby protein degradation. This compound is useful to differentiate phenotypic effects not caused by protein degradation in comparison with its active *trans* isomer ACBI1. Furthermore, the difference between binding to the bromodomain of SMARCA2 and SMARCA4 and its degradation can be studied *in vitro*.

SELECTIVITY DATA AVAILABLE	ACBI1	cis-ACBI1
SafetyScreen44™ with kind support of 	Yes	Yes
Invitrogen®	No	No
DiscoverX®	No	No
Dundee	No	No

The PROTAC ACBI1 was tested by the Eric Fisher Laboratory - Dana-Farber Cancer Institute as part of their Degradation Proteomics Initiative^{6,7}. It induces selective degradation of SMARCA2 and SMARCA4 after 5 h of treatment at 1 μ M in the neuroblastoma cell line Kelly Cells.




Figure 7: Global protein quantification was used to explore the unbiased proteome-wide selectivity of ACBI1 induced degradation. Whole cell protein quantification was performed using label free quantification with the Fischer lab's diaPASEF workflow.

Of the 7,742 proteins quantified in this experiment, only SMARCA2 and SMARCA4 were found to be significantly downregulated in response to ACBI1 treatment. Statistical analysis was performed using a moderated t-test in Bioconductor's limma package to generate hit lists containing log₂ Fold Change and P-values for each protein. The data are also displayed in the scatterplot above.

Co-crystal structure of the Boehringer Ingelheim probe compound and the target protein.

X-ray co-crystal structures of the targets in complex with ACBI1 analogs are available (PDB codes: 6HAZ, 6HAY, 6HAX and 6HR2)¹.

Reference molecule(s)

None available.

Supplementary data

2D structure files can be downloaded free of charge from [opnMe](#).

References

1. Farnaby W., Koegl M., Roy M. J., Whitworth C., Diers E., Trainor N., Zollman D., Steurer S., Karolyi-Oezguer J., Riedmueller C., Gmaschitz T., Wachter J., Dank C., Galant M., Sharps B., Rumpel K., Traxler E., Gerstberger T., Schnitzer R., Petermann O., Greb P., Weinstabl H., Bader G., Zoephel A., Weiss-Puxbaum A., Ehrenhöfer-Wölfer K., Wöhrle S., Boehmelt G., Rinnenthal J., Arnhof H., Wiechens N., Wu M.-Y., Owen-Hughes T., Ettmayer P., Pearson M., McConnell D. B., Ciulli A. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design *Nat Chem Biol* **2019**, 15(7), 672–680 DOI: [10.1038/s41589-019-0294-6](#), [DOI: 10.1038/s41589-019-0294-6](#), [PubMed: 31178587](#).
2. Churcher I. Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones? *J Med Chem* **2018**, 61(2):444-452. DOI: [10.1021/acs.jmedchem.7b01272](#), [PubMed: 29144739](#).
3. Webb T., Craigon C., Ciulli A. Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective *Bioorg Med Chem Lett* **2022**, 63:128653. DOI: [10.1016/j.bmcl.2022.128653](#), [PubMed: 35257896](#).
4. Vangamudi B., Paul T. A., Shah P. K., Kost-Alimova M., Nottebaum L., Shi X., Zhan Y., Leo E., Mahadeshwar H. S., Protopopov A., Futreal A., Tieu T. N., Peoples M., Heffernan T. P., Marszalek J. R., Toniatti C., Petrocchi A., Verhelle D., Owen D. R., Draetta G., Jones P., Palmer W. S., Sharma S., Andersen J. N. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies *Cancer Research* **2015**, 75(18), 3865–3878 DOI: [10.1158/0008-5472.CAN-14-3798](#), [PubMed: 26139243](#).

5. Soares P., Gadd M. S., Frost J., Galdeano C., Ellis L., Epemolu O., Rocha S., Read K. D., Ciulli A. Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase: Structure–Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy- N -(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298) *J Med Chem* **2018**, 61(2), 599–618. [DOI: 10.1021/acs.jmedchem.7b00675](https://doi.org/10.1021/acs.jmedchem.7b00675), [PubMed: 28853884](https://pubmed.ncbi.nlm.nih.gov/28853884/).
6. The data can be accessed via the following link: [Proteomics Dashboard \(fischerlab.org\)](https://proteomics.fischerlab.org)
7. Donovan K. A., Ferguson F. M., Bushman J. W., Eleuteri N. A., Bhunia D., Ryu S., Tan L., Shi K., Yue H., Liu X., Dobrovolsky D., Jiang B., Wang J., Hao M., You I., Teng M., Liang Y., Hatcher J., Li Z., Manz T. D., Groendyke B., Hu W., Nam Y., Sengupta S., Cho H., Shin I., Agius M. P., Ghobrial I. M., Ma M. W., Che J., Buhrlage S. J., Sim T., Gray N. S., Fischer E. S. Mapping the Degradable Kinome Provides a Resource for Expedited Degradation Development *Cell* **2020**, 183(6):1714-1731. [DOI: 10.1016/j.cell.2020.10.038](https://doi.org/10.1016/j.cell.2020.10.038), [PubMed: 33275901](https://pubmed.ncbi.nlm.nih.gov/33275901/).